Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine.

ABSTRACT:

Background

Marburg virus (MARV) is the causative agent of Marburg virus disease (MVD) which has a case fatality rate up to ∼90% in humans. Recently, there were cases reported in Guinea and Ghana highlighting this virus as a high-consequence pathogen potentially threatening global public health. There are no licensed treatments or vaccines available today. We used a vesicular stomatitis virus (VSV)-based vaccine expressing the MARV-Angola glycoprotein (VSV-MARV) as the viral antigen. Previously, a single dose of 1 × 10⁷ plaque-forming units (PFU) administered 7 days before challenge resulted in uniform protection from disease in cynomolgus macaques.

Methods

As we sought to lower the vaccination dose to achieve a higher number of vaccine doses per vial, we administe

SUBMITTER: O'Donnell KL 

PROVIDER: S-EPMC9947254 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature